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Tuesday, February 5, 2013 403aextracellular domain (ECD) of CaSR with various spectroscopic methods in-
cluding the tryptophan fluorescence titration, circular dichroism (CD) and nu-
clear magnetic resonance (NMR) as well as molecular dynamic simulation.
These results provide important implications for our understanding of how
the CaSR integrates information about these two completely different classes
of agonists–an inorganic divalent cation, and another hand, a nutrient– how the
receptor senses these agonists in healthy and diseased states.
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Combretastatins, which are an important group of anticancer drugs,were iso-
lated by Pettit et al. from the African tree Combretum caffrum in 1989. Addi-
tionally, Liang et al. have reported that ten coumestans were isolated fromthe
roots of Hedysarum multijugum, which is a plant in Hedysarum Linn. of the
family Leguminosae used as a folk herbal drug in northwest China. Coumestans
comprise a class of naturally occurring products with a variety of biological ac-
tivities including phytoestrogenic, antibacterial, antifungal, antimyotoxic, and
phytoalexine effects. The anticancer properties of demethylwedelolactone
(DWEL) and wedelolactone (WEL), which are naturally occurring coumestans,
have not been well characterized. Due to their biological activities, the synthe-
sis of DWEL is achieved in which the longest linear sequence is only eight
steps in 38% overall yield from commercially available phloroglucinol. Furth-
more, the molecular model was examined the interactions of proteins and li-
gands as well. Finally, in this study, we investigated the anti-invasive effects
of synthetic WEL and DWEL on human MDA-MB-231 breast cancer cells.
We found that WEL and DWEL inhibited the anchorage-independent growth
and also suppressed cell motility and cell invasion of MDA-MB-231 cells. In
addition, WEL and DWEL reduced the activity and expression of matrix metal-
loproteinases (MMPs) involved in blocking the IkB-a/NFkB and MEK/ERK
signaling pathways in MDA-MB-231 cells. Furthermore, DWEL suppressed
the metastasis and lung colonization of the tumor cells in the nude mice. Alto-
gether, these data suggest that DWEL derivatives exert anti-invasive growth ef-
fect on breast cancer cells.
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Histone methyltransferases are enzymes that modify histone proteins via meth-
ylation of lysine or arginine residues. These epigenetic modifiers, such as
DOT1L and EZH2, have been found to play important roles in leukemogenic
processes.
Crystallographic and docking methods studied interactions within the DOT1L
binding site. Crystal structures of DOT1L also demonstrated variance in the
binding mode of ligands, possibly due to rearrangement in the DOT1L binding
site. We investigated this possibility by molecular dynamics (MD) simulations
and confirmed significant rearrangement of the substrate binding and activation
loops of DOT1L upon binding to competitive inhibitors. The druggability and
volume fluctuations of the binding pocket over time were determined.
The EZH2 methyltransferase is of interest due to its aberrant activity in many
cancers. Because there is no published crystal structure of EZH2, we used ho-
mology modeling with homologous proteins as templates. This model provides
structural information regarding the binding
modes of the S-adenosyl methionine (SAM)
cofactor and potential inhibitors of EZH2.
Through the synergistic combination of
in silico drug design, organic synthesis
and biochemical assays, our modeling ef-
forts for DOT1L and EZH2 will guide the
chemical syntheses of potent and selective
inhibitors of these enzymes.2071-Pos Board B90
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T cell receptors (TCRs) recognize peptides bound and presented by major his-
tocompatibility complex (MHC) proteins using multiple complementarity de-
termining region (CDR) loops. While numerous analyses have illuminatedstructural and biophysical aspects of TCR recognition, how the distribution
of binding free energy within TCR-pMHC interfaces promotes unique TCR
recognition features, including MHC restriction and the apparent dichotomy
of specificity and cross-reactivity, remains unclear. Utilizing double mutant cy-
cles, here we performed a comprehensive structural and thermodynamic decon-
struction of the interaction between the A6 TCR and the Tax peptide presented
by the class I MHC HLA-A2. In contrast with general expectations, we ob-
served that the central regions of the peptide and its interactions with the hyper-
variable CDR3 loops contribute little to specificity, instead promoting by
dynamic effects the cross-reactivity that is a hallmark of TCR recognition.
We also observed that TCR restriction towards HLA-A2 results from not
from conserved interactions with the germline loops, but instead from strong
interactions with the hypervariable CDR3 loop of the a chain. Formation of
these latter interactions, however, is dependent upon the unique structural prop-
erties of the peptide, highlighting that TCR specificity towards peptide and
MHC can emerge from the need to engage a unique, composite peptide/
MHC interface with tightly coupled structural properties.
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Multidrug (MD) (or xenobiotic) e,ux actively removes cytotoxic chemicals
from the interiors of normal-functioning cells. However, high levels of
e,ux can render drug-targeted cells resistant to a broad-range of therapeutic
agents, including those to which cells were never exposed. Key multidrug
resistance (MDR) contributors include allosteric e,ux pumps, gene regulators
and other sensory systems that mediate the detection and extrusion of diverse
drugs from cellular environments. To date, MDR functions remain only par-
tially understood. Ligand-dependent allosteric control in BmrR has been quan-
titatively addressed using in vitro transcription experiments, dose-response
curves and thermodynamic models that relate the observed transcriptional
responses to ligand binding and changes in BmrR conformation. Preliminary
results indicate that allosteric control in BmrR is sensitive to both energetic
and structural aspects of ligand recognition. Importantly, increased coopera-
tivity in signal control relative to recognition implicates a major allosteric
role for the RNA polymerase.
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Dihydropteroate synthase (DHPS) is an essential enzyme in the bacterial folate
biosynthetic pathway. It catalyzes the condensation of 6-hydroxymethyl-7,8-
dihydropterin pyrophosphate (DHPP) with p-aminobenzoic acid (pABA) to
form the folate intermediate, 7,8-dihydropteroate. DHPS is the target of the
sulfonamide class of antibiotics. Widespread resistance to sulfonamides has de-
creased their clinical use. The active site of DHPS is comprised of three sub-
sites: the structured ‘‘pterin’’ site, the flexible pABA site, and the anion binding
pocket. Most of the drug resistant mutations have been mapped to the pABA
sub-site of DHPS. using an NMR ligand-based screening approach, a number
of structurally unrelated fragment-like small molecules have been identified
that inhibit the enzymatic activity of DHPS from Bacillus anthracis (Ba), Yer-
sinia pestis (Yp), and Staphylococcus aureus (Sa). Fragment hits were shown to
target the three sub-pockets of the active site and a novel site distinct from the
active site. The latter site potentially inhibits via an allosteric mechanism and
has been characterized by high resolution X-ray crystallography.
We screened the Maybridge Fragment library of 1,100 fragments using water
ligand observed gradient spectroscopy (waterLOGSY) as a primary screen
which resulted in a hit rate of 6.7 %. Of the 74 hits, 25 were shown to inhibit
DHPS activity using two independent enzyme activity assays. A total of eight
compounds inhibited the activity of DHPS from three different species (Ba, Yp,
and Sa). In addition to screening for inhibition, the fragment hits were validated
using a number of biophysical techniques including 2D NMR, SPR, competi-
tion waterLOGSY, and X-ray crystallography. Herein, we focus on two frag-
ment hits for which high-resolution x-ray crystal structures are available
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Photoreactive molecules like aryl azides play important role in life sciences,
as practical tools to achieve precisely timed covalent cross-links between li-
gands and targets. Since the azido group is small, stable and biologically inert,
404a Tuesday, February 5, 2013azido-modified aromatic drug molecules can keep their original pharmacolog-
ical activity. By photoactivating of such modified molecules in vivo, both
their strong and weak partners can be captured. Moreover, applying the azi-
dated drug in a concentration range and utilizing proteomic tools the apparent
binding constants of protein-ligand interactions can be determined.
We have developed a new and simple technique to azidate aromatic drug mol-
ecules in an easy two step reaction. Using our method we have synthesized
azidoblebbistatin which is a new derivative of blebbistatin, the most widely
used myosin inhibitor. In the absence of UV irradiation azidoblebbistatin
and blebbistatin exhibits identical inhibitory properties. Using UV light azido-
blebbistatin can be covalently crosslinked to myosin whereas the unbound in-
hibitor molecules become inactive. Using Dictyostelium discoideum cell
lysate we performed interactomic investigation to identify the previously un-
known targets of blebbistatin utilizing the self- fluorescence of azidoblebbista-
tin. Since the crosslinking was performed applying increasing concentration of
azidoblebbistatin, densitometry of the fluorescent spots resulting from gelelec-
trophoresis revealed the apparent binding constant of azidoblebbistatin. In case
of myosin II it was the exact value as measured in in vitro tests. With this tech-
nique the strongest interactant was found to be myosin II (EC50=5 mM) while
eight weak partners (EC50>30 mM) were also detected including vacuolar
Hþ-ATPase (EC50=50 5 31 mM), malate dehydrogenase (EC50=55 5
17 mM) and elongation factor 1a (EC50>100 mM).
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Plasmodium falciparum is the parasite responsible for the most deadly cases of
malaria. Emerging drug resistance to current therapies requires research to de-
velop new antimalarials. A potential target of new drugs is the proteolytic
egress cascade, which has been identified as essential to the blood stage para-
site. A key protein in the cascade is subtilisin-like protease 1 (SUB1). This pro-
tease undergoes two self-cleavage events to separate the N-terminal
prodomain, necessary for correct folding, from the C-terminal, catalytic do-
main. To obtain protein suitable for crystallization, we have expressed SUB1
both in bacterial and insect cell systems. However, recovery is difficult and
yield is often low. To improve the yield and purity of the protein, we employ
a selective affinity purification scheme developed in the lab. Our SPR valida-
tion assays indicate specific binding of a protein originating from either insect
cell or bacterial expression of recombinant SUB1. The possibility of producing
active SUB1 in bacterial systems after undergoing limited proteolysis is also
being explored and validated via SPR analysis. Determining dissociation con-
ditions and residues important to the interaction via mutational studies will pro-
vide a more comprehensive understanding of this protease and aid in future
structure based drug design.
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Pseudomonas aeruginosa (PA) is an opportunistic pathogen that causes lung in-
fections in cystic fibrosis and other immune-compromised individuals. The
most toxic factor secreted by PA is a 66 kDa protein, exotoxin A (ExoA), which
belongs to a larger (mART) family of enzymes that catalyze the transfer of the
ADP-ribosyl moiety from NADþ to a protein target.
COMPUTATIONAL APPROACH: Here, we used the high resolution crystal
structure of cholix as the structural model system for ExoA. We considered
structures in complex with several ligands (NADþ and various inhibitors:
NAP, V30, etc.) in order to address the mode of ligand binding. All the anal-
yses were performed with the Molecular Operative Environment suite
(MOE.2011). For each residue in the pocket, the interaction energy was eval-
uated along with various other descriptors. Binding free energy was calcu-
lated according to the GBVI/WSA function. Based upon the consensus
features of the cholix:ligand complexes, a pharmacophore model was devel-
oped and was used to dock these molecules as standards for the purpose of
training, followed by the docking of a new inhibitor library (M-series) ob-
tained from an in silico screening against another mART toxin, Iota toxin
from C. perfringens.
EXPERIMENTAL APPROACH: A cell based assay was used for a coarse
screen of the potency of the M-series inhibitors based on the viability of C38
cystic fibrosis human lung cells treated with ExoA. Compound M19 arose asthe best inhibitor for protection of the cystic fibrosis human lung cell line
with an EC50 of 2 mM. Future research will involve improvement of the
M19 scaffold based on the information from computational approaches.
This work was funded by a Cystic Fibrosis Canada (CFC) summer studentship
to AP, a CFC Canada-Kin postdoctoral fellowship to MRL, and CFC operating
grant to ARM.
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Dengue viruses (DENV) are transmitted by mosquitoes and infect ~50 million
people annually with an additional 2.5 billion people at risk living in tropical
areas. However, there are no approved vaccines or antiviral therapies to combat
the disease. DENV genome is translates into a single polyprotein comprising 3
structural and 7 non-structural (NS) proteins. The polyprotein precursor is
cleaved by both host proteases and the two-component virus protease NS2B-
NS3. Thus, this protease is considered as a promising target for antiviral design.
In order to identify novel inhibitors of the DENV NS2B-NS3 protease we fo-
cused our strategy on the allosteric inhibitors capable of targeting the NS2B-
NS3 interaction rather than the NS3 active site. The computational protocol
was performed for 7,240- FDA-approved drugs retrieved from the ZINC data-
base. We firstly implement a structure-based virtual screening to identify a pre-
liminary set of inhibitors against the catalytic domain in active form of DENV
NS2B-NS3 by docking analysis. The preliminary set inhibitors was then used to
perform a consensus scoring of docking poses, based on scoring functions from
the DrugScore and Xscore packages. Six docked poses were ranked among the
top 50 compounds according to consensus scoring and were used to molecular
dynamics (MD) simulation and free-energy calculation. Three compounds be-
longing to the piperazine derivatives family were finally proposed as potential
inhibitors for DENV NS2B-NS3. These compounds target the allosteric-
binding site of protease so that compound binding produces a conformational
change able to affect the interaction among the protease and peptide substrates.
The computational drug discovery strategy employed in our study could be ap-
plied for the identification of inhibitors of other flaviviral proteases.
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Highly efficient and specific biomolecular recognition requires both affinity and
specificity. The stability of the complex is determined by the affinity while the
specificity is controlled by either partner binding to other competitive biomole-
cules discriminatively. Previous quantitative descriptions of biomolecular recog-
nition were mostly driven by improving the affinity prediction, but lack of
quantification of specificity. We developed a novel method SPA (SPecificity
and Affinity) based on our funneled energy landscape theory. The strategy is
to simultaneously optimize the quantified specificity of the ‘‘native’’ protein-
ligand complex discriminating against ‘‘non-native’’ binding modes and the af-
finity prediction. The benchmark testing of SPA shows the best performance
against 16 other popular scoring functions in industry and academia on both pre-
diction of binding affinity and ‘‘native’’ binding pose. For the target COX-2 of
nonsteroidal anti-inflammatory drugs, SPA
successfully discriminates the drugs from
the diversity set, and the selective drugs
from non-selective drugs. The remarkable
performance demonstrates that SPA has sig-
nificant potential applications in identifying
lead compounds for drug discovery.2079-Pos Board B98
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With a rapid increase in the number of high-resolution protein-ligand struc-
tures, the known protein-ligand structures can be used to gain insights into
how a ligand binds in a target protein. Based on the fact that the structurally
similar binding sites share information about their ligands, we have developed
a local structure alignment tool, G-LoSA (Graph-based Local Structure Align-
ment). Using G-LoSA, the known protein-ligand binding-site structure library
